Sustained Response to Eculizumab in a Patient With COVID-19–Associated Acute Thrombotic Microangiopathy of the Allograft Kidney: A Case Report

Shehzad Rehman, Angelo de Mattos, Megan Stack, Douglas Norman, Sarah Zapata, Pei Li Wang, Abdul Hai Mansoor, Vanderlene Kung, Nicole K. Andeen

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Acute thrombotic microangiopathy (TMA) developing in association with SARS-CoV-2 infection is a rare but recognized phenomenon in native kidneys. In the allograft kidney, a diagnosis of TMA has a broad etiologic differential, including antibody-mediated rejection and recurrent and de novo causes of TMA that affect the native kidney. Prior case reports have described plasma exchange or eculizumab use in patients with COVID-19–associated TMA. Herein, we describe the course of a kidney transplant patient with COVID-19–associated TMA with response to eculizumab that was sustained after medication withdrawal and review the literature on COVID-19–associated TMA of the allograft kidney.

Original languageEnglish (US)
Pages (from-to)1866-1869
Number of pages4
JournalTransplantation proceedings
Volume55
Issue number8
DOIs
StatePublished - Oct 2023

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Fingerprint

Dive into the research topics of 'Sustained Response to Eculizumab in a Patient With COVID-19–Associated Acute Thrombotic Microangiopathy of the Allograft Kidney: A Case Report'. Together they form a unique fingerprint.

Cite this